Key points are not available for this paper at this time.
Disitamab vedotin-toripalimab led to a significantly greater improvement in outcomes than chemotherapy among patients with untreated HER2-expressing locally advanced or metastatic urothelial cancer. (Funded by RemeGen and others; RC48-C016 ClinicalTrials.gov number, NCT05302284; ChinaDrugTrials.org.cn number, CTR20220348.).
Building similarity graph...
Analyzing shared references across papers
Loading...
Xinan Sheng
Gongqian Zeng
Cuijian Zhang
New England Journal of Medicine
Peking University
Sun Yat-sen University
Chinese Academy of Medical Sciences & Peking Union Medical College
Building similarity graph...
Analyzing shared references across papers
Loading...
Sheng et al. (Sun,) studied this question.
www.synapsesocial.com/papers/69dd26f4f0cb8f4dd535919f — DOI: https://doi.org/10.1056/nejmoa2511648